Inadequate penetration of antiviral agents through the stratum corneum of the skin may be one of the limiting factors in the topical therapy of recurrent cutaneous herpes simplex virus infections in humans. In vitro studies of the penetration of the nucleoside analog acyclovir (ACV) through guinea pig skin demonstrated a marked increase in drug flux when ACV was formulated in dimethyl sulfoxide (DMSO), compared with water or polyethylene glycol (PEG) as the vehicle. To examine whether the increased transcutaneous flux of ACV effected by DMSO was meaningful in vivo, topical 5% ACV in DMSO was evaluated for the treatment of cutaneous herpes simplex virus infection in guinea pigs and compared with topical 5% ACV in PEG. When compared with infection sites treated with the vehicle alone, ACV in DMSO produced a greater percent reduction than did ACV in PEG in median lesion number (8 versus 58%; P < 0.001), median lesion area (35 versus 73%; P = 0.001), and median lesion virus titer (21 versus 84%; P = 0.08). We conclude that DMSO is a highly effective vehicle for topical administration of ACV and is superior to PEG in our model. Careful choice of vehicle and consideration of transcutaneous penetration may be important for realization of the full potential of topical antiviral therapy in humans.
Development of an effective topical therapy for recurrent mucocutaneous herpes simplex virus (HSV) infections in immunologically normal humans has been difficult (16) . Acyclovir (ACV) is a new anti-herpesvirus compound which is 10-to 150-fold more potent in vitro than older drugs such as vidarabine or iodoxuridine (IDU). In addition, ACV is phosphorylated selectively to an active form in virus-infected cells and is nontoxic to uninfected mammalian cells over a wide range of concentrations (22) . The value of ACV applied intravenously, orally, and topically in the treatment of severe HSV infections in immunosuppressed hosts and in primary genital HSV infections has been documented (5, 7, 15, 25, 27) . However, the results of treatment of recurrent mucocutaneous HSV infections in normal subjects with topical 5% ACV in polyethylene glycol (PEG; Zovirax) were disappointing. Topical treatment of recurrent herpes simplex labialis and recurrent herpes genitalis effected a reduction in the excretion of virus from the lesions, but there was no change in the clinical course of infection (7, 24) .
Assessment of the reasons for the clinical failure of topical ACV therapy in the treatment of recurrent herpes labialis and genitalis has led to the conclusion that either ACV was applied too late to affect the natural course of recurrent HSV disease or that it did not penetrate the stratum corneum and reach infected cells in the lower layers of the epidermis in adequate concentrations (24) . To evaluate the latter possibility, we studied the flux of ACV through guinea pig skin in vitro from different drug vehicles and have compared these findings with the in vivo efficacy of two drug vehicle combinations in the topical treatment of an experimental HSV infection (10) . * Corresponding author.
MATERIALS AND METHODS
Experimental animals and virus. Hartley strain, outbred, female albino guinea pigs weighing 200 to 250 g each were obtained from Charles River Breeding Laboratories, Inc., Wilmington, Mass. The virus used in these studies was the laboratory strain HSV-1 E115, originally obtained from Andre Nahmias, Emory University, Atlanta, Ga. Virus stock for inoculation of guinea pigs was prepared in Vero cells (Flow Laboratories, Inc., Rockville, Md.) and contained 1 x 107 to 4 x 107 PFU/ml.
Penetration of ACV through guinea pig skin. Guinea pigs were shaved closely with electric clippers and sacrificed with ether. Care was taken to ensure that the stratum corneum was not injured during the process of clipping. Full mg for ACV-DMSO. The day of inoculation was designated as day zero. Treatment was begun 24 h after inoculation and continued for a total of 3 days (days 1 to 3). Regimens designated as two times per day were given at 9 a.m. and 9 p.m., and those designated as four times per day were given at 9 a.m., 1 p.m., 5 p.m., and 9 p.m. The drug and the corresponding drug vehicle were always tested opposite each other at the same rostral-caudal level. A treatment or vehicle was tested only once on each animal. Other details are described below.
Plaque assay for virus infectivity. Test fluids were diluted 1:10, and 0.2-ml samples of each dilution were inoculated in duplicate onto confluent layers of Vero cells in six-well plastic tissue culture plates (Linbro). After 1 h, the cell monolayers were overlaid with 2 ml of modified Eagle minimal essential medium (Flow Laboratories) containing 0.5% agarose, 5% heat-inactivated fetal bovine serum, and antibiotics. The monolayers were then incubated for 6 to 7 days in a 5% CO2 atmosphere at 37°C, and the number of plaques was determined by staining with neutral red.
Skin homogenates. Animals were sacrificed with ether on day 4 after infection, and the full-thickness skin of the back was removed by dissection. The square of skin from each of the six treatment areas was minced with a scissors and then homogenized in 4 ml of tissue culture medium (Tissumizer; Tekmar Co., Cincinnati, Ohio). Debris was pelleted by centrifugation, and the supernatants were frozen at -70°C until assay for infectivity was performed.
Measures of drug efficacy and statistical procedures. Regrown hair was removed with a depilatory, and the number of lesions in each treatment site on day 4 was tallied. Lesions enumerated ranged from erythema to 2.5-mm-diameter vesicles. The diameter of individual lesions was determined by a hand lens from photographs, and the total lesion area was computed for each infection site. Paired data (drug-drug vehicle) were evaluated by the Wilcoxon signed-rank test, with the value for the drug expressed as a percentage of the result for the vehicle. The percent differences between the drug treatment and the vehicle control for ACV-PEG and ACV-DMSO were compared by the Mann-Whitney rank sum procedure (6) . Other data were analyzed by Student's t test. All probability determinations were two tailed, and P S 0.05 was considered to be significant.
RESULTS
In vitro penetration of ACV through guinea pig skin. In vitro skin permeation studies were performed to examine the influence of the drug vehicle on the rate of ACV penetration through guinea pig skin. We first examined the flux of ACV through guinea pig skin in double-chamber diffusion cells, using aqueous 0.15 M NaCl solutions as both the donor and receiver solvents. The mean value of the permeability coefficient for ACV through clipped skin was 0.34 x 10-3 cm/h ( Table 1 , experiment 1). From this value and the value of the aqueous solubility (1.49 mg/ml), the maximum steady-state flux of ACV through guinea pig skin with 0.15 M NaCl as the donor solution was calculated to be (0.34 x 10-3 cm/h) x (1.49 mg/ml -0) = 0.51 pRg/cm2 per h (equation 2).
The rate of skin penetration of drugs can be enhanced by certain vehicles which affect the barrier properties of the skin. Examples include urea, alcohol-water mixtures, and DMSO (4, 20) . ACV-PEG and 100 ,u.l of 0.5% ACV in DMSO were applied to the exposed skin surface of the diffusion apparatus. The volume of the dose corresponded to the amount used for treatment of experimental HSV infection, but the concentration of ACV in DMSO was 1/10th that used in the in vivo studies (Fig. 1) . The mean flux of 5% ACV from PEG in three experiments was 0.14 ± 0.06 ,ug/Cm2 per h and, for 0.5% ACV in DMSO, 0.46 ± 0.16 ,ug/cm2 per h; P = 0.02. A higher concentration of ACV in DMSO would have a proportionately higher flux (Fick's Law; equation 2).
Preparation and manipulation of the skin in the animal model could affect the rate of ACV penetration and generate misleading therapeutic results. The application of a depilatory is known to decrease the resistance of the skin to drug penetration (28) , and inoculation of the skin by puncture of the stratum corneum could leave pathways of low resistance. To examine how the depilation and the inoculation process might affect the transfer of ACV through guinea pig skin and influence the treatment results, experiments were designed to obtain skin for the in vitro studies which would mimic the condition of the skin at the onset of drug administration. In the animal model, the hair is clipped, a depilatory is applied twice, the virus is applied with a vaccination gun, and 24 h later, drug treatment regimens are initiated. Shown in Table 1 (ii) 24 h after clipping and depilation (experiment 3), and (iii) 24 h after clipping, depilation, and 60 sterile skin punctures (experiment 4). The permeability coefficients obtained from the manipulated skins at a time corresponding to the start of treatment do not differ significantly from the values obtained from control skins which were prepared only with electric clippers. Although Kp may be increased immediately after the application of Nair and multiple punctures, our results imply that 24 h is sufficient time for the normal barrier properties of guinea pig skin to be restored.
Efficacy of topical ACV-PEG and ACV-DMSO against experimental cutaneous HSV-1 infection. Sixteen guinea pigs were infected in six different areas on the dorsum. Drug and drug vehicles were tested in pairs on opposite sides of the midline. PEG and 5% ACV-PEG were applied four times per day for 3 days on the two midback sites, and DMSO and 5% ACV-DMSO were given two times per day for 3 days on opposing sides at the level of the rump. The two infection sites on the shoulders were untreated. Treatments were begun 24 h after inoculation at a time when lesions were just beginning to form. Treatment duration was 3 days, so the results might reflect penetration of intact skin and lesion prevention rather than therapy of established lesions. Analysis of the number of lesions at each site on day 4 showed that ACV-DMSO reduced the median lesion count by 80% compared with the contralateral DMSO control areas (5 versus 25 lesions; P = 0.001). Treatment with ACV-PEG effected an 18% reduction in the median number of lesions compared with PEG alone (22 versus 30 lesions; P = 0.002).
There is growing evidence that the guinea pig back has a biological gradient along the rostral-caudal axis (3). We have found that fewer numbers of lesions develop rostrally (S. L. Spruance, unpublished data). Because this gradient could affect the degree of drug efficacy, we were unable to directly compare ACV-PEG and ACV-DMSO with the initial experimental design. A second experiment was performed in which the two combinations of drug and drug vehicle were tested an equal number of times on the midback and on the rump. The effect of ACV on lesion area and virus titer were included as additional measures of efficacy.
For the second experiment, 16 animals were infected at four sites on the midback and rump. Treatment with ACV-PEG, PEG, ACV-DMSO, and DMSO was administered as drug-drug vehicle pairs on opposite sides of the midline as described above, except that the different formulations were alternately applied to the midback or rump areas, and DMSO was given four times per day instead of twice. The efficacy of drug treatment at the midback and rump was similar, and the data were combined. For statistical analysis, the percent difference for each drug formulation compared with the corresponding vehicle was derived and applied in a signedrank procedure (drug versus drug vehicle) or rank sum test (ACV-PEG versus ACV-DMSO). The results for each preparation on three measures of lesion severity are shown in Table 2 . ACV-PEG and ACV-DMSO treatments significantly reduced all measures of lesion severity compared with the vehicle controls (P = <0.001 to 0.004), but the effect of ACV-DMSO was much greater. ACV-DMSO produced a greater change than ACV-PEG in median lesion number (8% versus 58%; P < 0.001), median lesion area (35% versus 73%; P = 0.001), and median lesion virus titer (21% versus 84%; P = 0.08).
DISCUSSION
Treatment with topical 5% ACV-PEG does not alter the clinical course of recurrent herpes simplex labialis or genita- lis (7, 24) . Since the drug is a potent antiviral agent effective against herpes simplex virus disease under other clinical circumstances, we have attributed the failure of topical therapy in recurrent infections to either late initiation of treatment or inadequate penetration of the drug through the stratum corneum (24) . A recently completed trial of topical ACV-PEG against prodromal and erythema-stage herpes labialis has yielded negative results, which makes it unlikely that late treatment alone is responsible for the lack of efficacy (S. (1), topical ACV-PEG was highly effective in a variety of animal models of cutaneous HSV disease, including the guinea pig dorsum (18, 22) , female guinea pig genitalia (11), mouse lip (17), lumbosacral and orofacial skin of hairless mice (12) , and lumbar skin of athymic nude mice (9) . Topical ACV-PEG may have succeeded in these studies because the inoculation process altered the integrity of the stratum corneum or alternate routes of absorption were available, so that the ability of the formulation to penetrate stratum corneum was not a critical determinant of the outcome. For example, inoculation in several mouse models was achieved by needle scratches (9, 12) or by thermal injury with a surgical cautery (17) , procedures which are likely to have abrogated the barrier properties of the skin. In the guinea pig genital model, ACV may have achieved significant systemic levels by absorption across the introital or vaginal mucosa (11) . The study on the guinea pig dorsum by Park et al. (18) was similar to ours. However, if inoculation stabs were close together or superimposed, more damage to the skin may have occurred than with the widely spaced injections we employed, or increased drug penetration may have resulted from their repeated use of a depilatory (28) .
Although for many years guinea pigs have been known to be susceptible to experimental HSV infection, Hubler et al. showed in 1974 that inoculation of the dorsal skin with HSV-1, using a specific vaccination instrument (Sterneedle), produced multiple, small pustular herpes lesions that ran a benign, self-limited course of 10 to 12 days, a duration VOL. 25, 1984 (2) used the model to evaluate antiviral drugs. The present report has determined that Stemeedle punctures do not increase the diffusion of ACV through guinea pig skin and has correlated transcutaneous flux of ACV with in vivo efficacy. We have also observed a rostral-caudal gradient in the number of lesions which can be induced, with fewer lesions developing at rostral sites on the dorsum. Drug efficacy appears to be independent of location. Alenius and Oberg (2) did not find differences in lesion severity score attributable to site, whereas Paquette and Hughes (Abstr. Annu. Meet. Am. Soc. Microbiol. 1982, S38, p. 241) have reported that HSV-1 titers in guinea pig skin are markedly higher at caudal dorsal than at rostral dorsal sites of inoculation. Auerbach and Auerbach (3) described a host of rostral-caudal biological differences in animals, possibly related to a primary embryonic gradient that occurs with the establishment of the nervous system. Lesion site should be examined as a potential variable when the Hubler guinea pig model is used.
The use of DMSO to enhance the activity of a topical antiviral agent was described by Tomlinson and MacCallum in 1968 (26) in their studies of IDU for the treatment of HSV infection in guinea pigs. The improved results with IDU in DMSO in the animal model led to a human trial of 5% IDU in DMSO against recurrent herpes labialis in a small number of subjects (13) . The results were clinically impressive but not' statistically significant (16) . Results with topical IDU in DMSO for the treatment of recurrent genital herpes have been mixed (19, 23) . Studies in which DMSO is used have been limited in the United States because it is an investigational substance regulated by the Food and Drug Administration, but our findings and the similar results of Alenius et ,al. (1) with ACV suggest that continued study of DMSO as a potential vehicle is warranted. In the present study, DMSO alone reduced lesion severity (Table 2 ). This effect may be due to its antiinflammatory activity (8) .
Reducing the clinical severity of recurrent HSV infections by topical therapy has been a long and frustrating endeavor for many investigators (16) . The rapid natural healing of the lesions, the great variability in severity of untreated lesions, and the barrier effect of the stratum corneum appear to be the major difficulties. The present studies have identified the importance of drug penetration in the guinea pig model and should stimulate drug vehicle development for human applications.
